MiNK Therapeutics, Inc.

General Information

We are a clinical stage biopharmaceutical company pioneering the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell (iNKT) therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer (NK) cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress graft-versus-host-disease (GvHD). Our proprietary platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. As such, we believe that our approach represents a highly versatile application for therapeutic development in cancer and immune diseases. We are leveraging our platform and manufacturing capabilities to develop a wholly owned or exclusively licensed pipeline of both native and engineered iNKT cells, and anticipate having multiple clinical and preclinical readouts in 2021 and 2022.

(Note: MiNK Therapeutics, Inc. downsized its IPO at pricing on Oct. 14, 2021, by pricing 3.33 million shares, down from 4.0 million shares in the prospectus, at $12 – the bottom of its $12-to-$14 price range – to raise $39.96 million.)

Employees: 31
Founded: 2017
Contact Information
Address 149 Fifth Avenue Suite 500 New York, NY 10010
Phone Number 212-994-8250
Web Address
View Prospectus: MiNK Therapeutics, Inc.
Financial Information
Market Cap $427.18mil
Revenues $0 mil (last 12 months)
Net Income $-17.76 mil (last 12 months)
IPO Profile
Symbol INKT
Exchange NASDAQ
Shares (millions): 3.3
Price range $12.00 - $12.00
Est. $ Volume $40.0 mil
Manager / Joint Managers Evercore/ William Blair
CO-Managers B. Riley, Inc./ Baird
Expected To Trade: 10/15/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change